Manual of Hypertension of the European Society of Hypertension, Third Edition (eBook, PDF)
Redaktion: Mancia, Giuseppe; Agabiti Rosei, Enrico; Dominiczak, Anna; Tsioufis, Konstantinos; Grassi, Guido
105,95 €
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
53 °P sammeln
105,95 €
Als Download kaufen
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
53 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
53 °P sammeln
Manual of Hypertension of the European Society of Hypertension, Third Edition (eBook, PDF)
Redaktion: Mancia, Giuseppe; Agabiti Rosei, Enrico; Dominiczak, Anna; Tsioufis, Konstantinos; Grassi, Guido
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The Manual of Hypertension of the European Society of Hypertension reflects emerging concepts that have the potential to impact diagnostic and therapeutic approaches to hypertension. Updating all material, this new edition also delves into a number of areas that have received heightened interest in recent years.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 16.94MB
The Manual of Hypertension of the European Society of Hypertension reflects emerging concepts that have the potential to impact diagnostic and therapeutic approaches to hypertension. Updating all material, this new edition also delves into a number of areas that have received heightened interest in recent years.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 674
- Erscheinungstermin: 6. Juni 2019
- Englisch
- ISBN-13: 9780429583346
- Artikelnr.: 56935484
- Verlag: Taylor & Francis
- Seitenzahl: 674
- Erscheinungstermin: 6. Juni 2019
- Englisch
- ISBN-13: 9780429583346
- Artikelnr.: 56935484
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Prof. Giuseppe Mancia is Professor Emeritus, University of Milano-Bicocca, President, European Society of Hypertension (ESH) Foundation, Chairman, ESH Educational Board, Past President: International Society of Hypertension, European Society of Hypertension, European Society of Clinical Investigation and Italian Society of Hypertension Prof. Guido Grassi is Full Professor of Internal Medicine at the Clinica Medica of the University of Milano-Bicocca and Director of the Clinica Medica Institute at S. Gerardo Hospital-Monza/Milano Professor Dame Anna F Dominiczak DBE MD FRCP FAHA FRSE FMedSci is Regius Professor of Medicine, Vice-Principal and Head of College of Medical, Veterinary and Life Sciences, University of Glasgow Prof. Konstantinos P. Tsioufis MD, PhD, FESC, FACC is Professor of Cardiology, University of Athens, Hippocratic Hospital, Athens, President of the Hellenic Society of Cardiology and President of European Society of Hypertension Prof. Enrico Agabiti Rosei is Professor Emeritus of Internal Medicine - University of Brescia, Former Director Clinica Medica Generale Department of Clinical and Experimental Sciences University of Brescia and Chairman Department of Medicine, Azienda Spedali Civili di Brescia
Section I: Background and Epidemiology. 1. History of the European Society
of Hypertension: Past, Present and Future. 2. Hypertension as a
Cardiovascular Risk Factor. 3. Hypertension and the Kidney. 4. Blood
Pressure Control in Europe and Elsewhere. 5. Socioeconomic Determinants.
Section II: Etiological and Pathophysiological Aspects. 6. Hemodynamic
Patterns in Hypertension. 7. Genetic Basis of Blood Pressure and
Hypertension. 8. Oxidative Stress, Inflammation, Immune System and
Hypertension. 9. Sodium and Potassium. 10. Structural Cardiovascular
Changes in Hypertension. 11. Early Vascular Ageing. 12. Autonomic
Dysfunction. 13. The Renin- Angiotensin-Aldosterone System. 14. Stress,
Stress Reduction and Hypertension: An Updated Review. Section III:
Associated Risk Factors: Pathogenetic Role and Risk Modification. 15.
Heart Rate as a Cardiovascular Risk Factor in Hypertension. 16. Obesity and
Obstructive Sleep Apnoea. 17. The Metabolic Syndrome in Hypertension. 18.
Psychosocial Risk Factors, Airborne Pollution, Hypertension and
Cardiovascular Diseases. 19. Serum Uric Acid, Blood Pressure and
Hypertension. 20. Dyslipidaemia in Hypertension. Section IV: Blood Pressure
Measurements. 21. Old and New Office Blood Pressure Measurement Approaches.
22. Pulse Pressure. 23. Central Blood Pressure. 24. Ambulatory Blood
Pressure Measurement. 25. Home Blood Pressure. 26. Day-Night Related
Events: Nighttime Blood Pressure Fall and Morning Blood Pressure Rise. 27.
Short-Term Blood Pressure Variability. 28. Exercise Blood Pressure: The
Prognostic Impact of Exercise Systolic Blood Pressure. Section V: Organ
Damage-Measurement/Clinical Value. 29. Cardiac Damage from Left Ventricular
Hypertrophy to Heart Failure. 30. Structural and Functional Aspects of
Brian Damage. 31. Large Artery Damage: Measurement and Clinical Importance.
32. Microcirculation. 33. Endothelial Damage. 34. Retinal Changes. Section
VI: Integrated Diagnostic Aspects. 35. The Integrated Diagnostic Approach
in General Medicine. 36. Management of Hypertension by the Hypertension
Specialist and the Hypertension Excellence Centres. Section VII:
Therapeutic Aspects. 37. Non-Pharmacological Interventions. 38. The
Protective Cardiovascular Effects of Antihypertensive Treatment. 39. The
Nephroprotective Effect of Antihypertensive Treatment. 40.
Antihypertensive Drug Classes. 41. Single-Pill Combination Treatments in
Hypertension. 42. The J-Curve Phenomenon. 43. A Polypill for Global
Cardiovascular Prevention: Current Data and Future Perspectives. 44.
Managing Adverse Effects and Drug Intolerance. 45. Adherence to Treatment
in Hypertension. 46. Residual Risk in Treated Patients. Section VIII:
Special Conditions. 47. Ethnic Factors in Hypertension. 48. Resistant
Hypertension: Medical Treatment. 49. Interventional Therapies for Essential
Eypertension. 50. Atrial Fibrillation and Arterial Hypertension. 51. The
Diabetic/Obese Hypertensive Patient (Including Metabolic Syndrome). 52.
Hypertension in Children and Adolescents. 53. Hypertensive Emergencies and
Urgencies. 54. Hypertension Associated with Peripheral Artery Disease. 55.
Hypertension in Pregnancy. 56. Drug-Induced Hypertension. 57. Hypertension
in Patients with Advanced Chronic Kidney Disease. 58. Blood Pressure
Management in Acute Stroke. 59. Blood Pressure Management in the Chronic
Post-Stroke Phase. 60. The Post-Transplant Patient with Hypertension.
Section IX: Secondary Hypertension. Diagnosis and Treatment. 61.
Renovascular Hypertension. 62. Primary Aldosteronism. 63. Pheochromocytoma
and Paraganglioma. Section X: Additional Aspects. 64. Follow-Up of the
Hypertensive Patient. 65. 2018 ESC/ESH Hypertension Guidelines.
of Hypertension: Past, Present and Future. 2. Hypertension as a
Cardiovascular Risk Factor. 3. Hypertension and the Kidney. 4. Blood
Pressure Control in Europe and Elsewhere. 5. Socioeconomic Determinants.
Section II: Etiological and Pathophysiological Aspects. 6. Hemodynamic
Patterns in Hypertension. 7. Genetic Basis of Blood Pressure and
Hypertension. 8. Oxidative Stress, Inflammation, Immune System and
Hypertension. 9. Sodium and Potassium. 10. Structural Cardiovascular
Changes in Hypertension. 11. Early Vascular Ageing. 12. Autonomic
Dysfunction. 13. The Renin- Angiotensin-Aldosterone System. 14. Stress,
Stress Reduction and Hypertension: An Updated Review. Section III:
Associated Risk Factors: Pathogenetic Role and Risk Modification. 15.
Heart Rate as a Cardiovascular Risk Factor in Hypertension. 16. Obesity and
Obstructive Sleep Apnoea. 17. The Metabolic Syndrome in Hypertension. 18.
Psychosocial Risk Factors, Airborne Pollution, Hypertension and
Cardiovascular Diseases. 19. Serum Uric Acid, Blood Pressure and
Hypertension. 20. Dyslipidaemia in Hypertension. Section IV: Blood Pressure
Measurements. 21. Old and New Office Blood Pressure Measurement Approaches.
22. Pulse Pressure. 23. Central Blood Pressure. 24. Ambulatory Blood
Pressure Measurement. 25. Home Blood Pressure. 26. Day-Night Related
Events: Nighttime Blood Pressure Fall and Morning Blood Pressure Rise. 27.
Short-Term Blood Pressure Variability. 28. Exercise Blood Pressure: The
Prognostic Impact of Exercise Systolic Blood Pressure. Section V: Organ
Damage-Measurement/Clinical Value. 29. Cardiac Damage from Left Ventricular
Hypertrophy to Heart Failure. 30. Structural and Functional Aspects of
Brian Damage. 31. Large Artery Damage: Measurement and Clinical Importance.
32. Microcirculation. 33. Endothelial Damage. 34. Retinal Changes. Section
VI: Integrated Diagnostic Aspects. 35. The Integrated Diagnostic Approach
in General Medicine. 36. Management of Hypertension by the Hypertension
Specialist and the Hypertension Excellence Centres. Section VII:
Therapeutic Aspects. 37. Non-Pharmacological Interventions. 38. The
Protective Cardiovascular Effects of Antihypertensive Treatment. 39. The
Nephroprotective Effect of Antihypertensive Treatment. 40.
Antihypertensive Drug Classes. 41. Single-Pill Combination Treatments in
Hypertension. 42. The J-Curve Phenomenon. 43. A Polypill for Global
Cardiovascular Prevention: Current Data and Future Perspectives. 44.
Managing Adverse Effects and Drug Intolerance. 45. Adherence to Treatment
in Hypertension. 46. Residual Risk in Treated Patients. Section VIII:
Special Conditions. 47. Ethnic Factors in Hypertension. 48. Resistant
Hypertension: Medical Treatment. 49. Interventional Therapies for Essential
Eypertension. 50. Atrial Fibrillation and Arterial Hypertension. 51. The
Diabetic/Obese Hypertensive Patient (Including Metabolic Syndrome). 52.
Hypertension in Children and Adolescents. 53. Hypertensive Emergencies and
Urgencies. 54. Hypertension Associated with Peripheral Artery Disease. 55.
Hypertension in Pregnancy. 56. Drug-Induced Hypertension. 57. Hypertension
in Patients with Advanced Chronic Kidney Disease. 58. Blood Pressure
Management in Acute Stroke. 59. Blood Pressure Management in the Chronic
Post-Stroke Phase. 60. The Post-Transplant Patient with Hypertension.
Section IX: Secondary Hypertension. Diagnosis and Treatment. 61.
Renovascular Hypertension. 62. Primary Aldosteronism. 63. Pheochromocytoma
and Paraganglioma. Section X: Additional Aspects. 64. Follow-Up of the
Hypertensive Patient. 65. 2018 ESC/ESH Hypertension Guidelines.
Section I: Background and Epidemiology. 1. History of the European Society
of Hypertension: Past, Present and Future. 2. Hypertension as a
Cardiovascular Risk Factor. 3. Hypertension and the Kidney. 4. Blood
Pressure Control in Europe and Elsewhere. 5. Socioeconomic Determinants.
Section II: Etiological and Pathophysiological Aspects. 6. Hemodynamic
Patterns in Hypertension. 7. Genetic Basis of Blood Pressure and
Hypertension. 8. Oxidative Stress, Inflammation, Immune System and
Hypertension. 9. Sodium and Potassium. 10. Structural Cardiovascular
Changes in Hypertension. 11. Early Vascular Ageing. 12. Autonomic
Dysfunction. 13. The Renin- Angiotensin-Aldosterone System. 14. Stress,
Stress Reduction and Hypertension: An Updated Review. Section III:
Associated Risk Factors: Pathogenetic Role and Risk Modification. 15.
Heart Rate as a Cardiovascular Risk Factor in Hypertension. 16. Obesity and
Obstructive Sleep Apnoea. 17. The Metabolic Syndrome in Hypertension. 18.
Psychosocial Risk Factors, Airborne Pollution, Hypertension and
Cardiovascular Diseases. 19. Serum Uric Acid, Blood Pressure and
Hypertension. 20. Dyslipidaemia in Hypertension. Section IV: Blood Pressure
Measurements. 21. Old and New Office Blood Pressure Measurement Approaches.
22. Pulse Pressure. 23. Central Blood Pressure. 24. Ambulatory Blood
Pressure Measurement. 25. Home Blood Pressure. 26. Day-Night Related
Events: Nighttime Blood Pressure Fall and Morning Blood Pressure Rise. 27.
Short-Term Blood Pressure Variability. 28. Exercise Blood Pressure: The
Prognostic Impact of Exercise Systolic Blood Pressure. Section V: Organ
Damage-Measurement/Clinical Value. 29. Cardiac Damage from Left Ventricular
Hypertrophy to Heart Failure. 30. Structural and Functional Aspects of
Brian Damage. 31. Large Artery Damage: Measurement and Clinical Importance.
32. Microcirculation. 33. Endothelial Damage. 34. Retinal Changes. Section
VI: Integrated Diagnostic Aspects. 35. The Integrated Diagnostic Approach
in General Medicine. 36. Management of Hypertension by the Hypertension
Specialist and the Hypertension Excellence Centres. Section VII:
Therapeutic Aspects. 37. Non-Pharmacological Interventions. 38. The
Protective Cardiovascular Effects of Antihypertensive Treatment. 39. The
Nephroprotective Effect of Antihypertensive Treatment. 40.
Antihypertensive Drug Classes. 41. Single-Pill Combination Treatments in
Hypertension. 42. The J-Curve Phenomenon. 43. A Polypill for Global
Cardiovascular Prevention: Current Data and Future Perspectives. 44.
Managing Adverse Effects and Drug Intolerance. 45. Adherence to Treatment
in Hypertension. 46. Residual Risk in Treated Patients. Section VIII:
Special Conditions. 47. Ethnic Factors in Hypertension. 48. Resistant
Hypertension: Medical Treatment. 49. Interventional Therapies for Essential
Eypertension. 50. Atrial Fibrillation and Arterial Hypertension. 51. The
Diabetic/Obese Hypertensive Patient (Including Metabolic Syndrome). 52.
Hypertension in Children and Adolescents. 53. Hypertensive Emergencies and
Urgencies. 54. Hypertension Associated with Peripheral Artery Disease. 55.
Hypertension in Pregnancy. 56. Drug-Induced Hypertension. 57. Hypertension
in Patients with Advanced Chronic Kidney Disease. 58. Blood Pressure
Management in Acute Stroke. 59. Blood Pressure Management in the Chronic
Post-Stroke Phase. 60. The Post-Transplant Patient with Hypertension.
Section IX: Secondary Hypertension. Diagnosis and Treatment. 61.
Renovascular Hypertension. 62. Primary Aldosteronism. 63. Pheochromocytoma
and Paraganglioma. Section X: Additional Aspects. 64. Follow-Up of the
Hypertensive Patient. 65. 2018 ESC/ESH Hypertension Guidelines.
of Hypertension: Past, Present and Future. 2. Hypertension as a
Cardiovascular Risk Factor. 3. Hypertension and the Kidney. 4. Blood
Pressure Control in Europe and Elsewhere. 5. Socioeconomic Determinants.
Section II: Etiological and Pathophysiological Aspects. 6. Hemodynamic
Patterns in Hypertension. 7. Genetic Basis of Blood Pressure and
Hypertension. 8. Oxidative Stress, Inflammation, Immune System and
Hypertension. 9. Sodium and Potassium. 10. Structural Cardiovascular
Changes in Hypertension. 11. Early Vascular Ageing. 12. Autonomic
Dysfunction. 13. The Renin- Angiotensin-Aldosterone System. 14. Stress,
Stress Reduction and Hypertension: An Updated Review. Section III:
Associated Risk Factors: Pathogenetic Role and Risk Modification. 15.
Heart Rate as a Cardiovascular Risk Factor in Hypertension. 16. Obesity and
Obstructive Sleep Apnoea. 17. The Metabolic Syndrome in Hypertension. 18.
Psychosocial Risk Factors, Airborne Pollution, Hypertension and
Cardiovascular Diseases. 19. Serum Uric Acid, Blood Pressure and
Hypertension. 20. Dyslipidaemia in Hypertension. Section IV: Blood Pressure
Measurements. 21. Old and New Office Blood Pressure Measurement Approaches.
22. Pulse Pressure. 23. Central Blood Pressure. 24. Ambulatory Blood
Pressure Measurement. 25. Home Blood Pressure. 26. Day-Night Related
Events: Nighttime Blood Pressure Fall and Morning Blood Pressure Rise. 27.
Short-Term Blood Pressure Variability. 28. Exercise Blood Pressure: The
Prognostic Impact of Exercise Systolic Blood Pressure. Section V: Organ
Damage-Measurement/Clinical Value. 29. Cardiac Damage from Left Ventricular
Hypertrophy to Heart Failure. 30. Structural and Functional Aspects of
Brian Damage. 31. Large Artery Damage: Measurement and Clinical Importance.
32. Microcirculation. 33. Endothelial Damage. 34. Retinal Changes. Section
VI: Integrated Diagnostic Aspects. 35. The Integrated Diagnostic Approach
in General Medicine. 36. Management of Hypertension by the Hypertension
Specialist and the Hypertension Excellence Centres. Section VII:
Therapeutic Aspects. 37. Non-Pharmacological Interventions. 38. The
Protective Cardiovascular Effects of Antihypertensive Treatment. 39. The
Nephroprotective Effect of Antihypertensive Treatment. 40.
Antihypertensive Drug Classes. 41. Single-Pill Combination Treatments in
Hypertension. 42. The J-Curve Phenomenon. 43. A Polypill for Global
Cardiovascular Prevention: Current Data and Future Perspectives. 44.
Managing Adverse Effects and Drug Intolerance. 45. Adherence to Treatment
in Hypertension. 46. Residual Risk in Treated Patients. Section VIII:
Special Conditions. 47. Ethnic Factors in Hypertension. 48. Resistant
Hypertension: Medical Treatment. 49. Interventional Therapies for Essential
Eypertension. 50. Atrial Fibrillation and Arterial Hypertension. 51. The
Diabetic/Obese Hypertensive Patient (Including Metabolic Syndrome). 52.
Hypertension in Children and Adolescents. 53. Hypertensive Emergencies and
Urgencies. 54. Hypertension Associated with Peripheral Artery Disease. 55.
Hypertension in Pregnancy. 56. Drug-Induced Hypertension. 57. Hypertension
in Patients with Advanced Chronic Kidney Disease. 58. Blood Pressure
Management in Acute Stroke. 59. Blood Pressure Management in the Chronic
Post-Stroke Phase. 60. The Post-Transplant Patient with Hypertension.
Section IX: Secondary Hypertension. Diagnosis and Treatment. 61.
Renovascular Hypertension. 62. Primary Aldosteronism. 63. Pheochromocytoma
and Paraganglioma. Section X: Additional Aspects. 64. Follow-Up of the
Hypertensive Patient. 65. 2018 ESC/ESH Hypertension Guidelines.